NCT03784521

Brief Summary

The aim of this study is to demonstrated efficacy of in-line filtration to reduce systemic inflammatory response syndrome (SIRS) ,specific organ dysfunction and complications in adult cardiac surgery. 486 patients undergoing cardiac surgery for acquired heart disease are 1:1 randomized into in-line filtration (study group) and non-filtration (control group). The incidence of SIRS, complications, daily SOFA (sequential organ failure assessment) score are compared between groups.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
486

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2018

Completed
24 days until next milestone

First Posted

Study publicly available on registry

December 24, 2018

Completed
10 days until next milestone

Study Start

First participant enrolled

January 3, 2019

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

March 15, 2024

Status Verified

March 1, 2024

Enrollment Period

4.5 years

First QC Date

November 30, 2018

Last Update Submit

March 14, 2024

Conditions

Keywords

SIRSIn-line filtrationCardiac surgery

Outcome Measures

Primary Outcomes (1)

  • Incidence of SIRS after cardiac surgery

    SIRS is diagnosed when patients have two or more of these criteria: 1.Heart rate \>90/min, 2.Temperature \>38 °C or \<36 °C, 3.Respiratory rate \>20/min or Paco2 \<32 mm Hg (4.3 kPa), and 4.White blood cell count \>12000/mm3 or \<4000/mm3 or \>10% immature band.

    SIRS is evaluated every 24 hours from immediate post-op to 96 hours postoperatively

Secondary Outcomes (8)

  • Daily SOFA score

    SOFA score is evaluated every 24 hours from immediate post-op to 96 hours postoperatively

  • Incidence of Operative mortality

    up to 1 month postoperatively

  • Incidence of Permanent Stroke

    up to 1 month postoperatively

  • Incidence of Renal Failure

    up to 1 month postoperatively

  • Incidence of Prolonged Ventilation > 24 hours

    up to 1 month postoperatively

  • +3 more secondary outcomes

Study Arms (2)

In-line filtration

EXPERIMENTAL

For patients randomized to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used for all intravenous access during operation and postoperative period in intensive care unit (ICU).

Device: In-line filtration

Control

ACTIVE COMPARATOR

For patients randomized to control group, All intravenous access is managed routinely according to local standard care without filtration during operation and postoperative period in ICU.

Device: Standard care

Interventions

In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.

In-line filtration

Patients are treated with standard intravenous solutions and vascular access management

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients age 18 years or older undergoing elective adult cardiac surgery

You may not qualify if:

  • Emergency surgery
  • Patient who does not want to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ramathibodi Hospital

Bangkok, 10400, Thailand

Location

Related Publications (1)

  • Sasse M, Dziuba F, Jack T, Koditz H, Kaussen T, Bertram H, Beerbaum P, Boehne M. In-line Filtration Decreases Systemic Inflammatory Response Syndrome, Renal and Hematologic Dysfunction in Pediatric Cardiac Intensive Care Patients. Pediatr Cardiol. 2015 Aug;36(6):1270-8. doi: 10.1007/s00246-015-1157-x. Epub 2015 Apr 7.

    PMID: 25845941BACKGROUND

Study Officials

  • Narongrit Kantathut, MD

    Ramathibodi hospital, Mahidol University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 30, 2018

First Posted

December 24, 2018

Study Start

January 3, 2019

Primary Completion

June 30, 2023

Study Completion

June 30, 2023

Last Updated

March 15, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations